Engineers Create Hydrogels to Monitor Activity in the Body

Why It Matters

Flexible, injectable bioelectronics could replace rigid implants, lowering surgical risk and expanding continuous health monitoring capabilities.

Key Takeaways

• Granular hydrogels made from conductive polymer PEDOT:PSS.
• Injectable, printable, flow like liquid, solidify after placement.
• Enable real-time monitoring of neural signals in living tissue.
• Potential to replace rigid implantable sensors and electrodes.
• Patent pending; commercialization pathway being pursued.

Pulse Analysis

Traditional implantable monitors rely on metal, silicon or rigid plastics, demanding invasive surgery and often mismatching the mechanical properties of soft tissue. Conductive polymers such as PEDOT:PSS have emerged as biocompatible alternatives, but integrating them into flexible, conformable formats has remained a challenge. The new granular hydrogel approach sidesteps these limits by assembling microscopic, electrically active beads that retain conductivity while behaving like a soft, moldable paste. This hybrid of electronics and soft matter opens a pathway for devices that can be delivered through a needle and then adapt to complex organ geometries.

The hydrogel’s unique rheology—liquid under shear, solid when static—enables both injection and 3D printing, allowing clinicians to tailor electrode shapes to patient‑specific anatomy. Its micron‑scale porosity supports cell infiltration and nutrient flow, making it suitable for long‑term tissue integration. In proof‑of‑concept tests, the material captured local field potentials from locust antennae, confirming its ability to record neural activity without rigid contacts. Such capabilities suggest future uses in brain‑computer interfaces, cardiac mapping, and smart scaffolds that both support regeneration and provide real‑time physiological feedback.

Commercially, the technology aligns with a rapidly growing market for minimally invasive biosensors, projected to exceed $10 billion by 2030. With a pending U.S. patent and support from Washington University’s technology office, the team is positioned to license the platform to medical‑device firms. Regulatory pathways may be streamlined by the hydrogel’s biocompatibility and its potential to combine sensing with drug‑delivery functions, offering a single‑step therapeutic solution that could reduce procedural costs and improve patient outcomes.